UF Health researchers have used a promising approach by integrating CRISPR-cas9-based drug screening with patients’ clinical outcome to identify genes and pathways that predict how patients will respond to the standard firstline chemotherapy treatment regimen used to treat patients with acute myeloid leukemia, or AML.